Literature DB >> 25765210

Words of wisdom. Re: Testosterone treatment is a potent tumor promoter for the rat prostate.

Jason M Scovell1, Peter Butler1, Ranjith Ramasamy1, Dolores J Lamb2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25765210      PMCID： PMC4988524          DOI： 10.1016/j.eururo.2014.12.049

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  5 in total

Review 1.  Risks of testosterone-replacement therapy and recommendations for monitoring.

Authors:  Ernani Luis Rhoden; Abraham Morgentaler
Journal:  N Engl J Med       Date:  2004-01-29       Impact factor: 91.245

2.  Goodbye androgen hypothesis, hello saturation model.

Authors:  Abraham Morgentaler
Journal:  Eur Urol       Date:  2012-06-16       Impact factor: 20.096

3.  The Testosterone Trials: Seven coordinated trials of testosterone treatment in elderly men.

Authors:  Peter J Snyder; Susan S Ellenberg; Glenn R Cunningham; Alvin M Matsumoto; Shalender Bhasin; Elizabeth Barrett-Connor; Thomas M Gill; John T Farrar; David Cella; Raymond C Rosen; Susan M Resnick; Ronald S Swerdloff; Jane A Cauley; Denise Cifelli; Laura Fluharty; Marco Pahor; Kristine E Ensrud; Cora E Lewis; Mark E Molitch; Jill P Crandall; Christina Wang; Matthew J Budoff; Nanette K Wenger; Emile R Mohler; Diane E Bild; Nakela L Cook; Tony M Keaveny; David L Kopperdahl; David Lee; Ann V Schwartz; Thomas W Storer; William B Ershler; Cindy N Roy; Leslie J Raffel; Sergei Romashkan; Evan Hadley
Journal:  Clin Trials       Date:  2014-06       Impact factor: 2.486

Review 4.  Metabolic epidemiology of prostatic cancer.

Authors:  E L Wynder; K Laakso; M Sotarauta; D P Rose
Journal:  Prostate       Date:  1984       Impact factor: 4.104

5.  Influence of N-methyl-N-nitrosourea, testosterone, and N-(4-hydroxyphenyl)-all-trans-retinamide on prostate cancer induction in Wistar-Unilever rats.

Authors:  D L McCormick; K V Rao; L Dooley; V E Steele; R A Lubet; G J Kelloff; M C Bosland
Journal:  Cancer Res       Date:  1998-08-01       Impact factor: 12.701
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.